HCPLive Podcasts HCPLive.com

Episode Highlights:

0:16 Intro

0:28 Overview of presentation

0:38 Acne and post-inflammatory hyperpigmentation

01:35 Approaches to take

03:21 Rosacea, use of dermoscopy and symptomatology assessment

04:59 Necessity of inclusivity in clinical trials, other knowledge gaps

06:05 Images used in education


The American Academy of Dermatology (AAD) Annual Meeting in 2024 featured Dr. Andrew Alexis, a prominent figure in dermatology. Dr. Alexis, currently serving as the vice-chair for diversity in the department of dermatology and a professor of clinical dermatology at Weill Cornell Medical College in New York, presented a talk titled "Controversies in Acne and Rosacea."


In the interview, he shed light on critical aspects of managing acne and rosacea, particularly focusing on patients with skin of color.


Dr. Alexis advocated for inclusivity in clinical trials to improve understanding across diverse patient populations. He stressed the importance of expanding public awareness of rosacea in communities with skin of color and suggested incorporating diverse images into educational materials to better represent the spectrum of affected individuals.


Dr. Alexis's insights underscore the necessity of tailored approaches and increased inclusivity in dermatological research and education to better serve patients with diverse skin tones and backgrounds.


For additional information covered at the 2024 AAD conference, visit us at: https://www.hcplive.com/conference/aad.

In the medical community, a revolving cast of players plays a pivotal role in advancing scientific discovery and enhancing patient outcomes. During the research stage, a collaborative team effort, from the clinical trial sponsors to research sites and patient populations, is essential to ensure smooth progress and sustain momentum toward the finish line. 

The latest episode of New Insight with Veeral Sheth, MD features a conversation with Brad Doerschuk, the CEO of InFocus Clinical Research, on the important role of contract research organizations (CROs) in retina and the field of ophthalmology.

In their conversation, Sheth and Doerschuk shed light on the role of CROs in managing clinical trials, dive into the evolution of the retina space in recent decades, and describe the challenges in recruiting for trials of new agents.

Episode Highlights
0:00 Introduction
0:52 What is a CRO?
2:13 Development of InFocus
6:45 Discussing the retina pipeline
11:46 Recruitment challenges, solutions
15:50 Developing new clinical trial sites
18:19 Relationship between investigators, CROs
19:56 Shift in FDA guidance
23:14 New trial endpoints
25:16 Conclusion

Every episode of New Insight is available on HCPLive.com and be sure to subscribe to our channel on Spotify and Apple Podcasts. Please direct any podcast-related inquiries to show producer Connor Iapoce at ciapoce@mjhlifesciences.com.

A special double-episode of New Insight with Veeral Sheth, MD features a well-rounded conversation on all things ophthalmology with returning guest David Eichenbaum, MD, the director of research for Retina Vitreous Associates of Florida, as well as first-time guest Roger Goldberg, MD, a vitreoretinal surgeon at Bay Area Retina Associates.

The trio of retina specialists discuss recent conference news, the anniversary of a landmark agent, and what’s to come in 2024 for the specialty.

Episode Highlights:
0:00 Introduction
1:25 Entering 2024
7:34 The importance of treatment efficacy
12:09 Re-engaging GA treatment
15:05 Comparing aflibercept 8 mg and faricimab
23:00 Real-world data sets
26:30 What’s to come in 2024
27:45 Intravitreal gene therapies
31:00 Port delivery system
36:00 Wrapping-up 

Every episode of New Insight is available on HCPLive.com and be sure to subscribe to our channel on Spotify and Apple Podcasts. Please direct any podcast-related inquiries to show producer Connor Iapoce at ciapoce@mjhlifesciences.com.

In every episode of New Insight, Veeral Sheth, MD, Director of Clinical Trials at University Retina in Chicago, takes an in-depth look at the biggest news in ophthalmology and the behind the scenes work involved in eye care, with a rotation of guest experts involved in ophthalmic research, development, and clinical care.

The latest episode of New Insight features a conversation with Ocuphire Pharma’s CEO on the company’s flagship retinal product and leading a small, but high-powered research team.

Episode Highlights:
0:04 Introduction
1:23 History of Ocuphire Pharma
3:50 Leading a small, high-functioning team
6:41 Magrath’s background and journey
11:02 APX3330 for Diabetic Retinopathy
15:20 2024 Plans for Ocuphire
18:53 Addressing unmet needs
20:20 Outro

Every episode of New Insight is available on HCPLive.com and be sure to subscribe to our channel on Spotify and Apple Podcasts. Please direct any podcast-related inquiries to show producer Connor Iapoce at ciapoce@mjhlifesciences.com.

On the floor at AAO 2023, host Veeral Sheth, MD, and producer Connor Iapoce discuss UBX1325 for patients with diabetic macular edema, based on the 48-week results from the phase 2 BEHOLD study.

Episode Highlights:
0:30 Introduction
0:48 Background into UBX1325 and BEHOLD
2:49 BEHOLD 48-week results
6:05 Next steps
6:56 Conclusion

Please direct any podcast-related inquiries to ciapoce@mjhlifesciences.com.

Episode Highlights

0:12 Intro
1:24 Challenges in autoimmune hepatitis
3:30 Patient demographics
4:25 Diagnostic challenges
6:35 What is overlap syndrome?
8:04 Mysteries behind immune dysregulation
9:05 Promising drugs in investigation
10:51 The BAFF receptor target
11:41 Infliximab & rituximab
12:38 An autoimmune hepatitis wishlist
15:29 Outro

Autoimmune hepatitis (AIH), a rare liver disease characterized by an unclear driver of inflammation, is historically challenged by limited clinical understanding, a slow development of treatment options in investigation, and a nonetheless concerning prognosis for affected adults and children.

While some prospects are in development to aid specialists in adequately identifying risk factors for, diagnosing and treating AIH, education and communication on those developments is vital.

In an interview with HCPLive during the American College of Gastroenterology (ACG 2023) Annual Scientific Meeting in Vancouver, BC this week, Gina Choi, MD, associator clinical professor of medicine and surgery at UCLA Health, discussed the ins and outs of modern autoimmune liver disease research and development. 

Including the treatment pipeline and current standards for diagnostics, Choi additionally discussed the sociodemographic and pathophysiological traits of AIH burden—as well as the lesser-known overlap syndrome.

For more hepatology and gastroenterology coverage from ACG 2023, visit us at https://www.hcplive.com/conference/acg.